Adicet Bio, Inc. · NASDAQ:ACET

Adicet Bio — Investor Presentation (January 2024)

37 slides from Adicet Bio's investor presentation, Jan 16, 2024

  1. Slide 1: Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer

    Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer January 16, 2024 γδ= Gamma delta; CAR= Chimeric antigen receptor

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" of Adicet Bio, Inc. (Adicet or the Company) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. These forward-looking statements include, but are n

  3. Slide 3: Developing Broad Pipeline of Allogeneic γδ1 T Cell Therapies for AI and Cancer

    Program Target Potential Diseases Research IND-Enabling Clinical Status ADICET WHOLLY OWNED PROGRAMS ADI-001 CD20 Autoimmune IND in LN cleared Dec 2023 Initiate LN Phase 1 2Q 2024 Update planned 2H 2024 AI expansion opportunities ADI-001 CD20 NHL MCL Phase 1 ongoing* Update planned 2H 2024 ADI-270 C

  4. Slide 4: Adicet Bio Leadership Team

    Adicet Bio Leadership Team Francesco Galimi, M.D., Ph.D. Chief Medical Officer Chen Schor President and CEO Nick Harvey Chief Financial Officer Don Healey, Ph.D. Chief Technology Officer Blake Aftab, Ph.D. Chief Scientific Officer Amy Locke Head of Human Resources Nancy Boman, M.D., Ph.D. Chief Regu

  5. Slide 5: ADI-001 Autoimmune Diseases

    ADI-001 Autoimmune Diseases

  6. Slide 6: Adicet γδ1 CAR T Cell Therapy For Autoimmune Indications

    Exposure Consistent with Approved Autologous CAR T (Cmax, Day 28 Persistence and AUC) B-Cell Depletion Consistent with Autologous CD19 CAR T in SLE, SSC and IIM Preferentially Trafficking to Organs/ Tissues No Significant Risk of CRS, ICANS, or T cell Malignancies Compared to Autologous CAR T Readil

  7. Slide 7: CAR-T Cell Therapy Depleted B-cells and Achieved Treatment-Free Remissions in AI Diseases

    CAR-T Cell Therapy Depleted B-cells, Drove an Immune Reset, and Achieved Treatment-Free Remissions in Patients with AI Diseases1 1 CD19.CAR-T Cell in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First 15 Patients. ASH 2023 Note: Third-party data summarized on this slide

  8. Slide 8: Opportunity to Address Unmet Needs in B-Cell Mediated Autoimmune Diseases

    Opportunity to Address Unmet Needs in a Large Number of B-Cell Mediated Autoimmune Diseases POC for CAR-T mediated B-cell depletion demonstrated in multiple AI diseases Lupus and lupus nephritis1,2,3 Systemic sclerosis2 Idiopathic inflammatory myopathies2 Myasthenia gravis4,5 B-cell depletion via CD

  9. Slide 9: Cmax, D28 Persistence and AUC Consistent with Approved Autologous CD19 CAR T

    Cmax, D28 Persistence and AUC Consistent Values Reported for Approved Autologous CD19 CAR T1 1Badbaran, A. Cancers 2020;12, 1970; Locke et al. N Engl J Med 2022; 386:640-654; Neelapu et al. N EnglJ Med. 2017;377:2531-2544; Ogasawara et al. Clin Pharmacokinet 60, 1621–1633 (2021) D28= Day 28 xxx Dose

  10. Slide 10: γδ1 T Cells Preferentially Home to Tissues

    γδ1 T Cells Preferentially Home to Tissues peripheral blood10, 11 % of CD3+: ~1-3% γδ1 T cell lung9 tissue/blood: 9X liver7 tissue/blood: 3X skin8 tissue/blood: 8X GI6 tissue/blood: 11X breast5 tissue/blood: ~15X adipose tissue/blood: 9X lymph node3,4 CD27+ CD62L+ Vd1+ ↑↑ Vd2+ ↓↓ bone marrow2 tissue

  11. Slide 11: ADI-001 in AI Diseases: B-Cell Depletion Consistent with Autologous CD19 CAR T in SLE

    ADI-001 in AI Diseases: B-Cell Depletion Consistent with Autologous CD19 CAR T in SLE Academic Studies B-cell Depletion B-cell depletion data from ADI-001 trial in NHL mirrored experience of autologous CD19 CAR T in SLE1,2 B-cell depletion via CD20 targeting validated by CD20-targeted antibody (obin

  12. Slide 12: ADI-001 in AI Diseases: Off-the-Shelf with Advantageous Tissue Tropism and Safety

    ADI-001 in AI Diseases: B-Cell Depletion Consistent with Autologous CD19 CAR T “Off-the-Shelf” with Advantageous Tissue Tropism and Safety Profile B-cell depletion γδ1 T cell homing to tissues of interest B-cell depletion data from ADI-001 trial in NHL mirrors experience of autologous CD19 CAR T in

  13. Slide 13: ADI-001 Phase 1 Study Design: Lupus Nephritis

    ADI-001 Phase 1 Study Design: Lupus Nephritis Screening Lymphodepletion Treatment DLT Period (42 days) Follow Up LTFU Study Consent Day -28 Enrollment Single ADI-001 Infusion Day 1 Response/Safety Assessments Day 28 Response/Safety Assessments Months 3-6-9-12-18-24 Cyclophosphamide / Fludarabine Lym

  14. Slide 14: ADI-001 in Lupus Nephritis: Key Endpoints

    Levels of ADI-001 cells in peripheral blood Response to treatment: CR or PR on day 28 and month 3, 6, 9, 12, 18, 24 after infusion of ADI-001 Biomarkers associated with response to treatment: Antibody to dsDNA, antinuclear antibody (ANA) and complement levels Response per SLEDAI-2K/DORIS criteria AD

  15. Slide 15: ADI-001: Lupus Nephritis

    ADI-001: Lupus Nephritis Arthritis Rheum 2008 Jan;58(1):15-25. doi: 10.1002/art.23177.- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part 1. Hoover PJ et a;. Kidney Int 2016 Crampton, Steve P. et al. “Skin Malar rash Discoid rash CNS Spleen Splenomega

  16. Slide 16: ADI-001 Mantle Cell Lymphoma

    ADI-001 Mantle Cell Lymphoma

  17. Slide 17: ADI-001 Efficacy and Safety in Aggressive r/r B-cell NHL

    May 4, 2023 Data-cut date, n=24 evaluable patients. LBCL= Large B-cell lymphoma Demonstrated efficacy and favorable safety in 24 patients with aggressive r/r B-cell NHL Heavily pre-treated patients: median 4 prior lines of therapy with 50% prior CAR T Across All Doses: 71% ORR and 63% CR (LBCL & MCL

  18. Slide 18: GLEAN: ADI-001 First-in-Human Study

    GLEAN: ADI-001 First-in-Human Study (CD20 CAR+ γδ1 T cells) Follow-up Day -6/-5 Day 1 Day 28 Month 12 Long-term follow-up study Lympho- depletion (LD) Day 28 - response assessment Month 3, 6, 9 & 12 Response assessment Day 1 - ADI-001 infusion ADI-001 Dose (CAR+ Cells) (3 + 3 escalation design)* DL1

  19. Slide 19: ADI-001: Patient Characteristics

    ADI-001: Patient Characteristics 23 patients had aggressive B-cell lymphoma: 18 LBCL and 5 MCL; 1 patient enrolled with follicular lymphoma Most patients were heavily pre-treated with median four prior lines of therapy, relatively high tumor burden and poor prognostic outlook Twelve patients (50%) p

  20. Slide 20: ADI-001: Efficacy Summary by Dose Level

    ADI-001: Efficacy Summary by Dose Level Median No. of Prior Lines ORR (%) CR Rate (%) 6-month CR Rate (%) DL4 (RP2D; LBCL & MCL) 4 6/8 (75.0%) 5/8 (62.5%) 2/8 (25.0%) DL 4 MCL 4 2/2 (100.0%) 2/2 (100%) 2/2 (100%) All Doses (LBCL & MCL) 4 17/24 (70.8%) 15/24 (62.5%) 4/24 (16.7%) All Doses MCL 4 4/5 (

  21. Slide 21: ADI-001 Safety Summary by Dose Level

    DL1 (N=3) DL2 (N=3) DL3 (N=6) DL3 X2 (N=4) DL4 (N=8) Total (N=24) Any Grade Gr>=3 Any Grade Gr>=3 Any Grade Gr>=3 Any Grade Gr>=3 Any Grade Gr>=3 Any Grade Gr>=3 CRS 2 (66.7%) 0 0 0 1 (16.7%) 1 (16.7%) 4 (100.0%) 0 4 (50.0%) 0 11 (45.8%) 1 (4.2%) ICANS 0 0 1 (33.3%) 0 0 0 1 (25.0%) 1 (25.0%) 1 (12.5

  22. Slide 22: Strong CR Rate and Durability in 4L+ MCL Patients

    Strong CR Rate and Durability in 4L+ MCL Patients May 4, 2023 Data-cut date, n=24 evaluable patients; Data are subject to further review and verification. ORR: 80%, CR rate: 80%, 6-month CR rate: 60% No significant CRS or ICANS Day 1 Day 28 Month 6 Month 7 Month 5 Month 4 Month 3 Month 2 Month 12 Mo

  23. Slide 23: Data Provides Strong Foundation for Future Development in MCL

    Data Provides Strong Foundation for Future Development in MCL High CR rate Favorable durability in late-line patients Superior cell killing potency compared to autologous CAR T1 Cmax, Day 28 persistence and AUC consistent with approved CD19 autologous CAR T Favorable safety profile with no significa

  24. Slide 24: Focused Investments in Differentiated Early-Stage Pipeline

    Focused Investments in Differentiated Early-Stage Pipeline HvG=Host vs. Graft; RCC= Renal cell carcinoma; scFv= Single-chain fragment variable; TME= Tumor microenvironment IND submission in RCC expected 2Q 2024 Targeting CD70 via CD27-ligand has shown superiority to scFv CARs in preclinical studies

  25. Slide 25: ADI-270 Renal Cell Carcinoma

    ADI-270 Renal Cell Carcinoma

  26. Slide 26: ADI-270: Adicet's Armored CD70 CAR γδ1 T Cell

    ADI-270: Adicet’s Armored CD70 CAR γδ1 T Cell Targeting CD70 via CD27-ligand has shown superiority to scFv CARs1 Innate and adaptive targeting mechanisms associated with activity in RCC and other indications2 Armoring via dominant negative receptor; addresses TGFb in TME3 Next-generation CAR format

  27. Slide 27: Armored CAR Demonstrated Resilience Against TGFβ in Preclinical Models

    Armored CAR Demonstrated Resilience Against TGFβ and Maintained Potent Cytotoxic Function in Preclinical Models Armored ADI-270 cells are protected against TGFβ-mediated alterations to activation expression profile Armored CAR demonstrated improved serial killing Doses Genes down-regulated in TGF-β1

  28. Slide 28: CD70 CAR γδ1 T Cells Demonstrated Activity In Vivo and Proliferated Within Tumors

    CD70 CAR γδ1 T Cells Demonstrated Activity In Vivo and Proliferated Within Tumors Anti-tumor activity associated with CAR γδ1 T cell tumor infiltration and proliferation within the tumor bulk as evidenced by areas of marker colocalization noted with pink arrows Tumor Infiltration and Proliferation o

  29. Slide 29: Armored CD70 CAR γδ1 T Cell Opportunity For Differentiation

    Armored CD70 CAR γδ1 T Cell Opportunity For Differentiation ADC= Antibody-drug conjugate; AML= Acute myeloid leukemia; mAb= Monoclonal antibody; RCC= Renal cell carcinoma; SD= Stable disease; TME= Tumor microenvironment Opportunity for Adicet and γδ1 T cells Response to low antigen density by design

  30. Slide 30: ® Adicet Bio

    ® Adicet Bio € © pes 5) Oo = ou < = ” ou

  31. Slide 31: Armored PSMA CAR γδ1 T Cell Program

    Armored PSMA CAR γδ1 T Cell Program Allogeneic PSMA CAR γδ1 T cell therapy candidate for prostate cancer (PCa) Armoring demonstrated with TGFβ-DNR provides functional advantage for treating solid tumors Demonstrated penetration & killing in mCRPC primary tumor organoids Program: Historical challenge

  32. Slide 32: Lead PSMA CAR Binding Determinants Designed to be Consistent With Pluvicto

    Lead PSMA CAR Binding Determinants Designed to be Consistent With Pluvicto, The Only PSMA-Targeted Therapy With Validated Efficacy & Safety Profile Radioligand therapies bind the functional PSMA homodimer and are associated with a favorable efficacy and off-tissue AE profile, and is the only approve

  33. Slide 33: PSMA CAR γδ1 T-Cell Activity Observed in Primary Patient mCRPC Organoids

    PSMA CAR γδ1 T-Cell Activity Observed in Primary Patient mCRPC Organoids Adicet PSMA CAR and armored versions retained tumor control in TGFβ-secreting prostate cancer model Adicet’s unarmored lead CAR retained maximal control beyond 65 days at 3e6 CAR cell dose Benchmark CAR (J591) lost control of t

  34. Slide 34: CAR γδ1 T Cells Highly Active Against 22Rv1 Xenograft Model

    CAR γδ1 T Cells Highly Active Against 22Rv1 Xenograft Model, A Challenging Model With Intermediate & Heterogenous PSMA Expression 22Rv1 Tumors Express Intermediate and Heterogeneous PSMA Target-Associated Proliferation 22Rv1 (heterogeneous) PC3-PSMA (homogeneous) No target Untransduced Ctrl PSMA Vδ1

  35. Slide 35: Armored PSMA CAR γδ1 T Cell Opportunity For Differentiation

    Armored PSMA CAR γδ1 T Cell Opportunity For Differentiation Opportunity for Adicet and γδ1 T cells Potent CAR construct active against heterogeneous PSMA Three mechanisms of action designed to address tumor heterogeneity Homing of γδ1 T cells documented in mCRPC Inclusion of armoring to address supp

  36. Slide 36: Potential Near-Term Milestones

    Potential Near-Term Milestones 2024 2025 1H 2H 1H 2H ADI-001 MCL ADI-001 Autoimmune Diseases ADI-270 RCC Clinical Update ADI-270 IND Submission Study Enrollment Ongoing Initiate LN Phase 1 Expand to 1-2 additional AI Indications Preliminary Clinical Data in LN Preliminary Clinical Data in 1-2 additi

  37. Slide 37: Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer

    Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer

Adicet Bio — Investor Presentation (January 2024) on 6ix